Literature DB >> 8262726

Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.

O van Tellingen1, A V Kuijpers, J H Beijnen, W J Nooijen, A Bult.   

Abstract

We have investigated the pharmacokinetics of the investigational semi-synthetic vinca alkaloid vinorelbine (navelbine, NVB). The analyses have been performed by using a sensitive and selective method based on ion-exchange normal phase high-performance liquid chromatography with fluorescence detection combined with liquid-liquid extraction for sample clean-up. Pharmacokinetic studies were performed in male FVB mice receiving 12 mg/kg NVB through intravenous injection. The results have been compared to those obtained for vinblastine (VBL). The plasma pharmacokinetics of NVB can be described by a three compartment model. The elimination half-life is significantly longer and the plasma AUC values higher for NVB compared to VBL. This is reflected in tissues, where, 24 hr after drug administration, the concentration of NVB is 5 to 10-fold higher compared to VBL. Qualitatively, the tissue distribution and retention of the drugs is very similar. The drug concentrations in most tissues decline parallel with the circulating plasma levels, whereas prolonged retention is found in tissues of lymphatic and testicular origin. Deacetylation yielding deacetylnavelbine (DNVB) is the primary metabolic route for NVB. This cytotoxic metabolite accounts for a substantial part of the overall disposition of drug. Only 58% of the administered dose is excreted in the urine (17%) and faeces (41%) as NVB or DNVB. No other metabolites have been detected.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262726     DOI: 10.1007/bf00874148

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  29 in total

Review 1.  Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature.

Authors:  O Van Tellingen; J H Beijnen; W J Nooyen
Journal:  J Pharm Biomed Anal       Date:  1991       Impact factor: 3.935

2.  Phase-II study of Navelbine in advanced breast cancer.

Authors:  L Canobbio; F Boccardo; G Pastorino; F Brema; C Martini; M Resasco; L Santi
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

3.  Experimental antitumor activity of 5'-nor-anhydrovinblastine navelbine.

Authors:  R Maral; C Bourut; E Chenu; G Mathé
Journal:  Cancer Lett       Date:  1984-02       Impact factor: 8.679

4.  Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.

Authors:  A Pierré; L Kraus-Berthier; G Atassi; S Cros; M F Poupon; G Lavielle; M Berlion; J P Bizzari
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

5.  In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.

Authors:  X J Zhou; M Martin; M Placidi; J P Cano; R Rahmani
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

6.  Distribution and excretion of (3H)vincristine in the rat and the dog.

Authors:  M C Castle; D A Margileth; V T Oliverio
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

7.  Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection.

Authors:  O van Tellingen; A Kuijpers; J H Beijnen; M R Baselier; J T Burghouts; W J Nooyen
Journal:  J Chromatogr       Date:  1992-01-17

Review 8.  Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

Authors:  R W Dyke; R L Nelson
Journal:  Cancer Treat Rev       Date:  1977-06       Impact factor: 12.111

9.  Phase I pharmacologic study of a new Vinca alkaloid: navelbine.

Authors:  G Mathé; P Reizenstein
Journal:  Cancer Lett       Date:  1985-07       Impact factor: 8.679

10.  Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine).

Authors:  R Rahmani; M Martin; J Barbet; J P Cano
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

View more
  3 in total

Review 1.  Bioanalysis and pharmacokinetics of (investigational) vinca alkaloids.

Authors:  O van Tellingen
Journal:  Pharm World Sci       Date:  1994-06-10

Review 2.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

3.  Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer.

Authors:  Ramakrishna Samala; Helen R Thorsheim; Satyanarayana Goda; Kunal Taskar; Brunilde Gril; Patricia S Steeg; Quentin R Smith
Journal:  Pharm Res       Date:  2016-08-19       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.